News for Rezolute, Inc. (RZLT)

Biopharmaceutical company Rezolute, Inc. (RZLT) has announced the pricing of an underwritten public offering, aligning with Nasdaq regulations. This includes 20

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. ( RZLT) (”œRezolute” or the ”œCompany”), a late-stage biopharmaceutical company committed to

Rezolute, Inc. (RZLT) is moving forward with its Phase 3 sunRIZE clinical trial as planned, following positive feedback from the Data Monitoring Committee (DMC)

California-based Ensysce Biosciences, Inc. (ENSC) is up over 133 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

California-based Ensysce Biosciences, Inc. (ENSC) is up over 133 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

Rezolute, Inc. (RZLT) prices $90 million offering, targeting significant capital infusion. Major participation from prominent investors like Blackstone

Independent Data Monitoring Committee (the ”œDMC”) recommends continuation of sunRIZE trial as planned with no need to increase sample size Enrollment on tr

Shares of The AZEK Company Inc. AZEK rose sharply in today's pre-market trading after James Hardie Industries plc JHX announced plans to acquire the company for...

**media[568943]**

Rezolute (RZLT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

On February 28, 2025, FMR LLC (Trades, Portfolio) made a strategic move by acquiring 6,360,907 shares in Rezolute Inc at a purchase price of $4.43 per share. Th

California-based GigaCloud Technology Inc. (GCT) is down over 21 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

On February 18, 2025, Wladimir Hogenhuis, a Director at Rezolute Inc, purchased 10,000 shares of the company, as reported in a SEC Filing. Following this transa

Rezolute advances therapies for hypoglycemia with RZ358 and RZ402, showing efficacy in trials. Read why RZLT stock is a compelling, albeit cautious, investment.

Significant Transaction on December 31, 2024 On December 31, 2024, Nantahala Capital Management, LLC (Trades, Portfolio) executed a noteworthy transaction by ac

Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Designation and Orphan Drug Designa

**media[529004]**

If you are looking for stocks that are well positioned to maintain their recent uptrend, Rezolute (RZLT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism